Tiziana Life Sciences Ltd (TLSA) Form 6-K — Oct 16, 2026
Tiziana Life Sciences announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early/mild Alzheimer's disease, completing enrollment. Topline data are anticipated in Q1 2027. The trial tests foralumab both as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab, with endpoints including TSPO-PET-measured neuroinflammation, cognitive function, and amyloid/tau biomarkers.
Key figures
- Topline data timing
- Q1 2027
- Expanded access patients dosed
- 14
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.